3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Sarcoma
2
Breast
2
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
10
Breast Neoplasms
8
Ovarian Neoplasms
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Liposarcoma
1
Genital Neoplasms, Female
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
belinostat
2
Ifosfamide
2
Filgrastim
2
Doxorubicin
2
enzalutamide
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Midazolam
1
Letrozole
1
Immunotherapy
1
Imatinib Mesylate
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Cyproheptadine
1
Chemotherapy, Adjuvant
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liposarcoma
×
Fulvestrant
×
Genitourinary
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled